Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Gilead's $29B breast cancer buy

Posted 14 September 2020

Gilead has plumped out its oncology pipeline with the acquisition of Immunomedics, giving it a first-in-class antibody already approved by the FDA as a treatment for triple-negative breast cancer.

Trodelvy (sacituzumab govitecan-hziy) is a Trop-2 directed antibody-drug conjugate granted accelerated approval by the FDA in April in third-line metastatic triple-negative breast cancer (mTNBC).

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
PBAC March agenda
Every major and minor sub sorted by indication
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas
Special Report
November 2020 PBAC outcomes
Just over half of submissions recommended